ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 387

Left Ventricular Myocardial Tissue In Rheumatoid Arthritis Shows Systemic Inflammation After Fatal Myocardial Infarction 

Inge A.M. van Den Oever1, Alper M. van Sijl1, Umit Baylan2, Michael. T. Nurmohamed1, Alexandre E. Voskuyl1, Hans W. Niessen2 and Suat Simsek3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Pathology, VU University Medical Center, Amsterdam, Netherlands, 3Internal Medicine, Medical Center Alkmaar (MCA), Alkmaar, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, coronary artery disease, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with a chronic inflammatory disease (CID), particularly rheumatoid arthritis (RA), have an increased risk of fatal myocardial infarction (MI) and a diminished survival rate as compared to the general population. This risk might be explained, in part, by the systemic inflammatory process in CID. We investigated whether individuals with CID who developed a fatal myocardial infarction (MI) had an increased influx of inflammatory cells in different areas of myocardial tissue, as compared to individuals without CID.

 

Methods: Myocardial tissue of 11 individuals with CID (5 with RA, 4 with psoriasis, 2 with an inflammatory bowel disease) who died of a fatal MI were used. Controls were matched for age, gender and time elapsed between myocardial infarction and death. Myocardial tissue was immunohistochemically stained with specific antibodies against myeloperoxidase (neutrophilic granulocytes), CD45 (lymphocytes), CD68 (macrophages) and tryptase (mast-cells). Cell density (cells/mm2) was calculated for the right ventricular (RV) myocardium (internal control; remote area), left ventricular (LV-) myocardium free from MI (internal control) and left ventricular (LV+) myocardium of the MI for each stain. Differences in cell densities between the CID group and controls, and within these groups; between LV+, LV- and RV, were analysed using the non-parametric Mann-Whitney U test.

 

Results: The CID group and controls showed a similar propensity towards inflammatory cell influx in infarcted myocardium. However, in patients with RA, an increased influx of lymphocytes and macrophages was noted in LV+ as well as LV-, as compared to RV, lymphocyte density: 16.5 (p < 0.05) and 14.8 (p < 0.05) vs. 7.9, macrophage density: 17.1 (p < 0.05) and 20.3 (p < 0.05) vs. 9.9 (p < 0.05). These findings were not found in the control group. There was no significant influx of granulocytes or mast-cells in ventricular tissue of patients with RA.

 

Conclusion: Left ventricular myocardial tissue of patients with RA, showed an increased propensity towards systemic inflammation outside the regions of myocardial infarction. In particular, an increased influx of macrophages and lymphocytes was noted. This underlying inflammatory process in RA might enhance more cytokine release, thereby causing more cardiac depression and tissue damage after myocardial infarction.

 

Figure 1. Bar chart depicting the difference in inflammatory cell density of several types of myocardial tissue and the presence of rheumatoid arthritis

 

 



Disclosure:

I. A. M. van Den Oever,
None;

A. M. van Sijl,
None;

U. Baylan,
None;

M. T. Nurmohamed,
None;

A. E. Voskuyl,

Actelion Pharmaceuticals,

5;

H. W. Niessen,
None;

S. Simsek,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/left-ventricular-myocardial-tissue-in-rheumatoid-arthritis-shows-systemic-inflammation-after-fatal-myocardial-infarction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology